Publicaciones en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (34)

2024

  1. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

  2. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74

  3. Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study

    United European Gastroenterology Journal

  4. Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply

    Alimentary Pharmacology and Therapeutics

  5. Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 10, pp. 1248-1259

  6. Increased prevalence of migraine in women with inflammatory bowel disease: A cross-sectional study

    Cephalalgia : an international journal of headache, Vol. 44, Núm. 3

  7. Safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease

    Digestive and Liver Disease, Vol. 56, Núm. 3, pp. 468-476

  8. Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients

    Inflammatory Bowel Diseases, Vol. 30, Núm. 2, pp. 167-182

2023

  1. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  2. Idiopathic Thrombocytopaenic Purpura associated with Inflammatory Bowel Disease: a multicentre ECCO CONFER case series

    Journal of Crohn's and Colitis, Vol. 17, Núm. 5, pp. 722-727

  3. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 2, pp. 406-414.e7

  4. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

  5. Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review

    Journal of Crohn's and Colitis, Vol. 17, Núm. 6, pp. 972-994

  6. Splanchnic Vein Thrombosis in Inflammatory Bowel Disease: An Observational Study from the ENEIDA Registry and Systematic Review

    Journal of Clinical Medicine, Vol. 12, Núm. 23

2022

  1. Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series

    Journal of Crohn's and Colitis, Vol. 16, Núm. 6, pp. 940-945

  2. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  3. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  4. Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy

    Therapeutic Advances in Gastroenterology, Vol. 15

  5. Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry

    Digestive and Liver Disease, Vol. 54, Núm. 5, pp. 635-641

  6. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15